<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on July 28, 2020</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT03663543</url>
  </required_header>
  <id_info>
    <org_study_id>82378</org_study_id>
    <nct_id>NCT03663543</nct_id>
  </id_info>
  <brief_title>Intravenous Estrogen in Kidney Transplant Study</brief_title>
  <acronym>PERT</acronym>
  <official_title>The Use of Peri-Operative Intravenous Estrogen for the Mitigation of Ischemia Reperfusion Injury in the Setting of Renal Transplantation</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>University of Pennsylvania</agency>
      <agency_class>Other</agency_class>
    </lead_sponsor>
    <collaborator>
      <agency>Pfizer</agency>
      <agency_class>Industry</agency_class>
    </collaborator>
  </sponsors>
  <source>University of Pennsylvania</source>
  <oversight_info>
    <has_dmc>Yes</has_dmc>
    <is_fda_regulated_drug>Yes</is_fda_regulated_drug>
    <is_fda_regulated_device>No</is_fda_regulated_device>
  </oversight_info>
  <brief_summary>
    <textblock>
      Ischemia perfusion injury (IRI) is a major cause of organ injury during kidney
      transplantation. Currently there are no treatments for IRI other than dialysis. Preliminary
      studies in female mice have found protection from IRI when given short term estrogen
      supplements. This study will look at the effect of intravenous estrogen given
      peri-operatively to reduce the effect of IRI in female kidney transplant recipients.
    </textblock>
  </brief_summary>
  <detailed_description>
    <textblock>
      Ischemia-reperfusion injury (IRI) is a major etiology of organ injury and dysfunction that
      occurs during transplantation. In renal transplantation, the clinical manifestation of IRI is
      delayed graft function (DGF), typically defined as a recipient requiring dialysis within the
      first week after transplant. At present, there are no directed treatments for IRI associated
      with kidney transplantation and resultant DGF, other than supportive care with dialysis. This
      represents an unmet clinical need. While dialysis enables the support of patients until DGF
      resolves, DGF is associated with increased medical costs, increased length of hospital stay,
      increased rates of readmission to the hospital after transplantation, increased rates of
      rejection, and decreased graft survival. Therapies to reduce IRI might alleviate clinical
      complications associated with DGF, reduce costs associated with transplantation, and ease
      organ shortages by facilitating use of more marginal organs.

      Despite acceptance of gender disparities in IRI tolerance in animal systems, attempts to
      utilize hormonal manipulation in humans to achieve improved IRI tolerance have not been
      undertaken. In an effort to design such a translation, the investigators investigated if
      similar gender disparities exist in humans who have undergone kidney transplantation. After
      review of the United Network for Organ Sharing database, the investigators established that
      male recipient gender was highly associated with DGF. Then, the investigators demonstrated
      that manipulation of the pre-ischemic environment with short-term estrogen supplementation in
      female mice provides protection from renal IRI. As a logical next stop, the investigators
      propose hormonal manipulation with perioperative administration of intravenous conjugated
      estrogens as a novel therapeutic strategy to reduce the effect of IRI in female humans
      undergoing kidney transplantation. The investigators have designed an investigational new
      drug (IND) late phase I/early phase II prospective, single center, double blind, randomized,
      placebo-controlled trial to test the safety, feasibility, and efficacy of this therapy. If
      the administration of peri-operative intravenous administration has a positive impact on the
      rate of recovery of GFR after renal transplant and the inherent IRI, then this therapy would
      represent the first treatment for IRI and ultimately might reduce the incidence of DGF.
      Because DGF after kidney transplantation is associated with inferior transplant outcomes and
      increased costs,2 a therapy that mitigates the effect of IRI and consequently reduces the
      incidence of DGF not only might alleviate these complications but could also ease organ
      shortages by facilitating the use of more marginal organs. Moreover, if estrogen therapy does
      mitigate IRI in the setting of renal transplantation, it could be applied to other causes of
      renal IRI including supra-celiac clamping in trauma or vascular surgery or the use of
      cardiopulmonary bypass in cardiac surgery. Female adult subjects with a diagnosis of end
      stage renal disease who are dialysis dependent at the time of deceased donor renal
      transplantation and meet the inclusion and exclusion criteria will be eligible for
      participation in this study.
    </textblock>
  </detailed_description>
  <overall_status>Recruiting</overall_status>
  <start_date type="Actual">August 26, 2016</start_date>
  <completion_date type="Anticipated">January 31, 2022</completion_date>
  <primary_completion_date type="Anticipated">January 31, 2022</primary_completion_date>
  <phase>Phase 1/Phase 2</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>Randomized</allocation>
    <intervention_model>Parallel Assignment</intervention_model>
    <intervention_model_description>Parallel: Participants are assigned to one of two or more groups in parallel for the duration of the study</intervention_model_description>
    <primary_purpose>Treatment</primary_purpose>
    <masking>Triple (Participant, Care Provider, Investigator)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>Glomerular filtration rate (GFR)</measure>
    <time_frame>Post-operative day three</time_frame>
    <description>GFR (glomerular filtration rate) as calculated from a DTPA (Diethylenetriamine Pentaacetic Acid, a medication) renal scan.</description>
  </primary_outcome>
  <secondary_outcome>
    <measure>Delayed graft function (DGF)</measure>
    <time_frame>Immediately post-operative</time_frame>
    <description>Measurement of urine creatinine clearance and serum creatinine.</description>
  </secondary_outcome>
  <other_outcome>
    <measure>Graft Failure</measure>
    <time_frame>Post-operative day three and day ninety</time_frame>
    <description>Measurement of serum creatinine.</description>
  </other_outcome>
  <number_of_arms>2</number_of_arms>
  <enrollment type="Anticipated">30</enrollment>
  <condition>Ischemia Reperfusion Injury</condition>
  <arm_group>
    <arm_group_label>Active Arm</arm_group_label>
    <arm_group_type>Active Comparator</arm_group_type>
    <description>Participants randomized to the active arm will receive a single infusion of conjugated estrogens at the time of admission if within 8 hours of the expected surgery time or at approximately 8 hours to the expected surgery time if admission is earlier than that. Participants will then receive two daily infusions of conjugated estrogens after transplant given at 8 hours after reperfusion of the transplanted kidney and 24 hours after the first post transplant dose (32 hours after reperfusion of the transplanted kidney).</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Placebo Arm</arm_group_label>
    <arm_group_type>Placebo Comparator</arm_group_type>
    <description>Participants randomized to the placebo arm will receive normal saline (0.9% sodium chloride) at the same rate as the active arm.</description>
  </arm_group>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Conjugated Estrogen</intervention_name>
    <description>Dosing of conjugated estrogen will be given pre kidney transplant procedure and twice after reperfusion of the transplanted kidney.</description>
    <arm_group_label>Active Arm</arm_group_label>
    <other_name>Premarin</other_name>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Normal saline</intervention_name>
    <description>Dosing of normal saline will be given pre kidney transplant procedure and twice after reperfusion of the transplanted kidney.</description>
    <arm_group_label>Placebo Arm</arm_group_label>
    <other_name>0.9% sodium chloride</other_name>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:

          1. Female gender

          2. Age &gt; 21 years at time of transplant

          3. Pre-existing dialysis dependence of at least 1-months duration at the time of
             transplant

          4. Receiving a deceased donor renal transplant

          5. Receiving their first (primary) kidney transplant

          6. Subjects must receive between 500-5000U intravenous systemic heparin during their
             kidney transplant

          7. Subjects must receive between 2500-7500U subcutaneous heparin prophylaxis three times
             daily during hospital stay

          8. Written informed consent obtained from subject and ability for subject to comply with
             the requirements of the study

        Exclusion Criteria:

          1. Receiving a non-primary (second, third, fourth, etc.) kidney transplant

          2. Receiving a combined heart-kidney transplant, liver-kidney transplant, or other
             multi-visceral organ transplant

          3. Receiving a live donor kidney transplant

          4. Personal history of deep vein thrombosis (DVT) or pulmonary embolism (PE)

          5. Personal history of hypercoagulable condition including but not limited to Lupus
             Anticoagulant, Leiden Factor V Mutation, Prothrombin Gene Mutation, Protein C or S
             deficiency, or any other hypercoagulable condition considered by the attending
             transplant surgeon on clinical service or Data and Safety Monitoring Board (DSMB) to
             warrant exclusion from the study

          6. Personal history of an estrogen sensitive cancer (breast, endometrial, ovarian)

          7. Personal history of arterial thromboembolic disease such as stroke or myocardial
             infarction in the 6 months prior to transplantation

          8. Patient already on estrogen (including oral contraceptive pills) or anti-estrogen
             therapy for other indications

          9. Patient who is expected to not tolerate a dose of 500-5000U intravenous heparin at the
             time of transplant as determined by the transplant surgeon

         10. Patient who has a contraindication or allergy to or is expected to not tolerate a dose
             of 2500-7500U subcutaneous heparin prophylaxis three times daily during hospital stay
             as determined by the transplant surgeon

         11. Pregnant and breast feeding patients will be excluded from the study due to the small
             risk of radiation associated with the DTPA renal scan

         12. Patient body mass index (BMI) &gt; 40Kidney donor profile index (KDPI) &lt; 40

         13. Known anaphylactic reaction and angioedema to Premarin Intravenous therapy

         14. Presence of a condition or abnormality that in the opinion of the investigator or
             attending transplant surgeon primarily responsible for the patient's care would
             compromise the safety of the patient or the quality of the data
      </textblock>
    </criteria>
    <gender>Female</gender>
    <gender_based>Yes</gender_based>
    <gender_description>Participants must be female</gender_description>
    <minimum_age>21 Years</minimum_age>
    <maximum_age>N/A</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Matthew Levine, MD, PhD</last_name>
    <role>Principal Investigator</role>
    <affiliation>University of Pennsylvania Health System</affiliation>
  </overall_official>
  <overall_contact>
    <last_name>Mary C Shaw, RN</last_name>
    <phone>215-614-0528</phone>
    <email>mary.shaw@uphs.upenn.edu</email>
  </overall_contact>
  <location>
    <facility>
      <name>University of Pennsylvania</name>
      <address>
        <city>Philadelphia</city>
        <state>Pennsylvania</state>
        <zip>19104</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Mary C Shaw, RN</last_name>
      <phone>215-614-0528</phone>
      <email>mary.shaw@uphs.upenn.edu</email>
    </contact>
    <investigator>
      <last_name>Matthew L Levine, MD</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location_countries>
    <country>United States</country>
  </location_countries>
  <reference>
    <citation>Siedlecki A, Irish W, Brennan DC. Delayed graft function in the kidney transplant. Am J Transplant. 2011 Nov;11(11):2279-96. doi: 10.1111/j.1600-6143.2011.03754.x. Epub 2011 Sep 19. Review.</citation>
    <PMID>21929642</PMID>
  </reference>
  <reference>
    <citation>Kher A, Meldrum KK, Wang M, Tsai BM, Pitcher JM, Meldrum DR. Cellular and molecular mechanisms of sex differences in renal ischemia-reperfusion injury. Cardiovasc Res. 2005 Sep 1;67(4):594-603. Review.</citation>
    <PMID>15950202</PMID>
  </reference>
  <reference>
    <citation>Kher A, Wang M, Tsai BM, Pitcher JM, Greenbaum ES, Nagy RD, Patel KM, Wairiuko GM, Markel TA, Meldrum DR. Sex differences in the myocardial inflammatory response to acute injury. Shock. 2005 Jan;23(1):1-10. Review.</citation>
    <PMID>15614124</PMID>
  </reference>
  <reference>
    <citation>Hedges SJ, Dehoney SB, Hooper JS, Amanzadeh J, Busti AJ. Evidence-based treatment recommendations for uremic bleeding. Nat Clin Pract Nephrol. 2007 Mar;3(3):138-53. Review.</citation>
    <PMID>17322926</PMID>
  </reference>
  <reference>
    <citation>Wigginton JG, Pepe PE, Idris AH. Rationale for routine and immediate administration of intravenous estrogen for all critically ill and injured patients. Crit Care Med. 2010 Oct;38(10 Suppl):S620-9. doi: 10.1097/CCM.0b013e3181f243a9.</citation>
    <PMID>21164406</PMID>
  </reference>
  <reference>
    <citation>Bradley LD, Gueye NA. The medical management of abnormal uterine bleeding in reproductive-aged women. Am J Obstet Gynecol. 2016 Jan;214(1):31-44. doi: 10.1016/j.ajog.2015.07.044. Epub 2015 Aug 5. Review.</citation>
    <PMID>26254516</PMID>
  </reference>
  <reference>
    <citation>Murray AW, Barnfield MC, Waller ML, Telford T, Peters AM. Assessment of glomerular filtration rate measurement with plasma sampling: a technical review. J Nucl Med Technol. 2013 Jun;41(2):67-75. doi: 10.2967/jnmt.113.121004. Epub 2013 May 8. Review. Erratum in: J Nucl Med Technol. 2014 Dec;42(4):12A.</citation>
    <PMID>23658207</PMID>
  </reference>
  <results_reference>
    <citation>Ojo AO, Wolfe RA, Held PJ, Port FK, Schmouder RL. Delayed graft function: risk factors and implications for renal allograft survival. Transplantation. 1997 Apr 15;63(7):968-74.</citation>
    <PMID>9112349</PMID>
  </results_reference>
  <results_reference>
    <citation>Alves MG, Oliveira PJ, Carvalho RA. Substrate selection in hearts subjected to ischemia/reperfusion: role of cardioplegic solutions and gender. NMR Biomed. 2011 Nov;24(9):1029-37. doi: 10.1002/nbm.1640. Epub 2011 Jan 28.</citation>
    <PMID>21274961</PMID>
  </results_reference>
  <results_reference>
    <citation>Ardelt AA, Carpenter RS, Lobo MR, Zeng H, Solanki RB, Zhang A, Kulesza P, Pike MM. Estradiol modulates post-ischemic cerebral vascular remodeling and improves long-term functional outcome in a rat model of stroke. Brain Res. 2012 Jun 21;1461:76-86. doi: 10.1016/j.brainres.2012.04.024. Epub 2012 Apr 21.</citation>
    <PMID>22572084</PMID>
  </results_reference>
  <results_reference>
    <citation>Eckhoff DE, Bilbao G, Frenette L, Thompson JA, Contreras JL. 17-Beta-estradiol protects the liver against warm ischemia/reperfusion injury and is associated with increased serum nitric oxide and decreased tumor necrosis factor-alpha. Surgery. 2002 Aug;132(2):302-9.</citation>
    <PMID>12219027</PMID>
  </results_reference>
  <results_reference>
    <citation>Gabel SA, Walker VR, London RE, Steenbergen C, Korach KS, Murphy E. Estrogen receptor beta mediates gender differences in ischemia/reperfusion injury. J Mol Cell Cardiol. 2005 Feb;38(2):289-97. Epub 2005 Jan 20.</citation>
    <PMID>15698835</PMID>
  </results_reference>
  <results_reference>
    <citation>Peng X, Wang J, Lassance-Soares RM, Najafi AH, Sood S, Aghili N, Alderman LO, Panza JA, Faber JE, Wang S, Epstein SE, Burnett MS. Gender differences affect blood flow recovery in a mouse model of hindlimb ischemia. Am J Physiol Heart Circ Physiol. 2011 Jun;300(6):H2027-34. doi: 10.1152/ajpheart.00004.2011. Epub 2011 Mar 11.</citation>
    <PMID>21398592</PMID>
  </results_reference>
  <results_reference>
    <citation>Hu H, Wang G, Batteux F, Nicco C. Gender differences in the susceptibility to renal ischemia-reperfusion injury in BALB/c mice. Tohoku J Exp Med. 2009 Aug;218(4):325-9.</citation>
    <PMID>19638737</PMID>
  </results_reference>
  <results_reference>
    <citation>Müller V, Szabó A, Viklicky O, Gaul I, Pörtl S, Philipp T, Heemann UW. Sex hormones and gender-related differences: their influence on chronic renal allograft rejection. Kidney Int. 1999 May;55(5):2011-20.</citation>
    <PMID>10231466</PMID>
  </results_reference>
  <results_reference>
    <citation>Müller V, Losonczy G, Heemann U, Vannay A, Fekete A, Reusz G, Tulassay T, Szabó AJ. Sexual dimorphism in renal ischemia-reperfusion injury in rats: possible role of endothelin. Kidney Int. 2002 Oct;62(4):1364-71.</citation>
    <PMID>12234307</PMID>
  </results_reference>
  <results_reference>
    <citation>Park KM, Kim JI, Ahn Y, Bonventre AJ, Bonventre JV. Testosterone is responsible for enhanced susceptibility of males to ischemic renal injury. J Biol Chem. 2004 Dec 10;279(50):52282-92. Epub 2004 Sep 8.</citation>
    <PMID>15358759</PMID>
  </results_reference>
  <results_reference>
    <citation>Park KM, Cho HJ, Bonventre JV. Orchiectomy reduces susceptibility to renal ischemic injury: a role for heat shock proteins. Biochem Biophys Res Commun. 2005 Mar 4;328(1):312-7.</citation>
    <PMID>15670785</PMID>
  </results_reference>
  <results_reference>
    <citation>Robert R, Ghazali DA, Favreau F, Mauco G, Hauet T, Goujon JM. Gender difference and sex hormone production in rodent renal ischemia reperfusion injury and repair. J Inflamm (Lond). 2011 Jun 9;8:14. doi: 10.1186/1476-9255-8-14.</citation>
    <PMID>21658244</PMID>
  </results_reference>
  <results_reference>
    <citation>Rusai K, Prókai A, Szebeni B, Mészáros K, Fekete A, Szalay B, Vannay Á, Degrell P, Müller V, Tulassay T, Szabó AJ. Gender differences in serum and glucocorticoid regulated kinase-1 (SGK-1) expression during renal ischemia/reperfusion injury. Cell Physiol Biochem. 2011;27(6):727-38. doi: 10.1159/000330081. Epub 2011 Jun 17.</citation>
    <PMID>21691090</PMID>
  </results_reference>
  <results_reference>
    <citation>Shen SQ, Zhang Y, Xiong CL. The protective effects of 17beta-estradiol on hepatic ischemia-reperfusion injury in rat model, associated with regulation of heat-shock protein expression. J Surg Res. 2007 Jun 1;140(1):67-76. Epub 2007 Mar 2.</citation>
    <PMID>17336333</PMID>
  </results_reference>
  <results_reference>
    <citation>Soljancic A, Ruiz AL, Chandrashekar K, Maranon R, Liu R, Reckelhoff JF, Juncos LA. Protective role of testosterone in ischemia-reperfusion-induced acute kidney injury. Am J Physiol Regul Integr Comp Physiol. 2013 Jun 1;304(11):R951-8. doi: 10.1152/ajpregu.00360.2012. Epub 2013 Apr 3.</citation>
    <PMID>23552495</PMID>
  </results_reference>
  <results_reference>
    <citation>Wittnich C, Belanger MP, Askin N, Boscarino C, Wallen WJ. Lower liver transplant success in females: gender differences in metabolic response to global ischemia. Transplant Proc. 2004 Jun;36(5):1485-8.</citation>
    <PMID>15251365</PMID>
  </results_reference>
  <results_reference>
    <citation>Antus B, Liu S, Yao Y, Zou H, Song E, Lutz J, Heemann U. Effects of progesterone and selective oestrogen receptor modulators on chronic allograft nephropathy in rats. Nephrol Dial Transplant. 2005 Feb;20(2):329-35. Epub 2004 Dec 23.</citation>
    <PMID>15618244</PMID>
  </results_reference>
  <results_reference>
    <citation>Antus B, Yao Y, Song E, Liu S, Lutz J, Heemann U. Opposite effects of testosterone and estrogens on chronic allograft nephropathy. Transpl Int. 2002 Oct;15(9-10):494-501. Epub 2002 Sep 20.</citation>
    <PMID>12389082</PMID>
  </results_reference>
  <results_reference>
    <citation>Aufhauser DD Jr, Wang Z, Murken DR, Bhatti TR, Wang Y, Ge G, Redfield RR 3rd, Abt PL, Wang L, Svoronos N, Thomasson A, Reese PP, Hancock WW, Levine MH. Improved renal ischemia tolerance in females influences kidney transplantation outcomes. J Clin Invest. 2016 May 2;126(5):1968-77. doi: 10.1172/JCI84712. Epub 2016 Apr 18.</citation>
    <PMID>27088798</PMID>
  </results_reference>
  <results_reference>
    <citation>Livio M, Mannucci PM, Viganò G, Mingardi G, Lombardi R, Mecca G, Remuzzi G. Conjugated estrogens for the management of bleeding associated with renal failure. N Engl J Med. 1986 Sep 18;315(12):731-5.</citation>
    <PMID>3018561</PMID>
  </results_reference>
  <results_reference>
    <citation>Heistinger M, Stockenhuber F, Schneider B, Pabinger I, Brenner B, Wagner B, Balcke P, Lechner K, Kyrle PA. Effect of conjugated estrogens on platelet function and prostacyclin generation in CRF. Kidney Int. 1990 Dec;38(6):1181-6.</citation>
    <PMID>1963650</PMID>
  </results_reference>
  <results_reference>
    <citation>Viganò G, Gaspari F, Locatelli M, Pusineri F, Bonati M, Remuzzi G. Dose-effect and pharmacokinetics of estrogens given to correct bleeding time in uremia. Kidney Int. 1988 Dec;34(6):853-8.</citation>
    <PMID>2850395</PMID>
  </results_reference>
  <results_reference>
    <citation>DeVore GR, Owens O, Kase N. Use of intravenous Premarin in the treatment of dysfunctional uterine bleeding--a double-blind randomized control study. Obstet Gynecol. 1982 Mar;59(3):285-91.</citation>
    <PMID>6281704</PMID>
  </results_reference>
  <verification_date>June 2020</verification_date>
  <study_first_submitted>August 27, 2018</study_first_submitted>
  <study_first_submitted_qc>September 5, 2018</study_first_submitted_qc>
  <study_first_posted type="Actual">September 10, 2018</study_first_posted>
  <last_update_submitted>June 3, 2020</last_update_submitted>
  <last_update_submitted_qc>June 3, 2020</last_update_submitted_qc>
  <last_update_posted type="Actual">June 4, 2020</last_update_posted>
  <responsible_party>
    <responsible_party_type>Sponsor</responsible_party_type>
  </responsible_party>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Reperfusion Injury</mesh_term>
    <mesh_term>Ischemia</mesh_term>
  </condition_browse>
  <intervention_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Estrogens</mesh_term>
    <mesh_term>Estrogens, Conjugated (USP)</mesh_term>
  </intervention_browse>
  <patient_data>
    <sharing_ipd>No</sharing_ipd>
  </patient_data>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

